Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / CYTK - Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress | Benzinga


CYTK - Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress | Benzinga

  • Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy

    Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety

    SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), at Heart Failure 2024, an International Congress of the European Society of Cardiology, taking place in Lisbon, Portugal from May 11, 2024 – May 14, 2024.

    Title: Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM an International Multicenter Phase 3 Trial
    Presenter: Martin Maron, M.D., Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical Center
    Date: May 13, 2024
    Topic: Heart Failure Association
    Session Title: Late Breaking Clinical Trials: LVAD, HFpEF and Hypertrophic Cardiomyopathy
    Session Type: Late Breaking Science
    Session Time: 1:45-2:45 PM WEST
    Presentation Time: 2:09 PM WEST
    Location: Room 1

    Title: Enhancing Exercise Response in Obstructive HCM: Insights from Aficamten's Impact on Patients with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM
    Presenter: Gregory Lewis, M.D., Jeffrey and Mary Ellen Jay Chair and Section Head, Heart Failure Medical Director, Cardiopulmonary Exercise Testing Laboratory, Professor of Medicine, Harvard Medical School
    Date: May 13, 2024
    Topic: Heart Failure Association
    Session Title: Late Breaking Clinical Trials: LVAD, HFpEF and Hypertrophic Cardiomyopathy
    Session Type: Late Breaking Science
    Session Time: 1:45-2:45 PM WEST
    Presentation Time: 2:21 PM WEST
    Location: Room ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Cytokinetics Incorporated
    Stock Symbol: CYTK
    Market: NASDAQ
    Website: cytokinetics.com

    Menu

    CYTK CYTK Quote CYTK Short CYTK News CYTK Articles CYTK Message Board
    Get CYTK Alerts

    News, Short Squeeze, Breakout and More Instantly...